Edition:
United States

Mersana Therapeutics Inc (MRSN.OQ)

MRSN.OQ on NASDAQ Stock Exchange Global Select Market

12.17USD
17 Aug 2018
Change (% chg)

$-0.42 (-3.34%)
Prev Close
$12.59
Open
$12.58
Day's High
$12.68
Day's Low
$12.00
Volume
50,306
Avg. Vol
44,839
52-wk High
$23.67
52-wk Low
$8.76

Chart for

About

Mersana Therapeutics, Inc. is a biotechnology company. The Company is focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design... (more)

Overall

Beta: --
Market Cap(Mil.): $278.72
Shares Outstanding(Mil.): 22.90
Dividend: --
Yield (%): --

Financials

  MRSN.OQ Industry Sector
P/E (TTM): -- 99.36 30.45
EPS (TTM): -2.03 -- --
ROI: -72.12 2.89 12.63
ROE: -- 1.65 14.82

Mersana's cancer drug trial put on hold by FDA; shares halted

Mersana Therapeutics said on Thursday an early stage trial testing its lead cancer drug has been put on partial hold by the U.S. Food and Drug Administration after a patient's death was possibly linked to the treatment.

Jul 19 2018

Mersana Therapeutics cancer drug trial on partial hold by FDA

July 19 Mersana Therapeutics said on Thursday its early-stage trial for its cancer drug has been put on partial hold by the U.S. health regulator after a patient's death was possibly related to the treatment.

Jul 19 2018

BRIEF-Mersana Therapeutics Reports Q1 Loss Per Share $0.54

* MERSANA THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

May 14 2018

BRIEF-Mersana Therapeutics Q4 Loss Per Share $0.61

* MERSANA THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

Mar 28 2018

BRIEF-Mersana Appoints David Spellman As Chief Financial Officer

* MERSANA APPOINTS DAVID A. SPELLMAN AS CHIEF FINANCIAL OFFICER

Mar 12 2018

Earnings vs. Estimates